S16 Ep48: Shifting the Paradigm in Small Cell Lung Cancer: Targeting Tumor Biology to Transform Patient Outcomes

Highlights from the PER® CME activity "Shifting the Paradigm in Small Cell Lung Cancer: Targeting Tumor Biology to Transform Patient Outcomes" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Charles M. Rudin, MD, PhD; Alex A. Adjei, MD, PhD; and Millie Das, MD; discuss the latest treatment advances for extensive-stage small cell lung cancer (ES-SCLC), including how to sequence bispecific T-cell engagers and antibody-drug conjugates and ways to manage adverse events associated with these newer therapies.Earn CME credit by completing the full accredited activity (available through April 9, 2027):https://www.gotoper.com/stp26sclc-activityThis podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc; Merck Sharp & Dohme, LLC; and Jazz Pharmaceuticals, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.